| 1 |
34325497 |
10.4143/crt.2021.752 |
2022 |
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. |
PIM1 |
| 2 |
34448823 |
10.1182/bloodadvances.2021004212 |
2022 |
The molecular hallmarks of primary and secondary vitreoretinal lymphoma. |
PIM1 |
| 3 |
34714908 |
10.1182/bloodadvances.2021005486 |
2022 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. |
PIM1 |
| 4 |
34979782 |
10.3760/cma.j.cn112138-20210124-00066 |
2022 |
[Mucosal associated lymphoid tissue lymphoma with positive PIM1 expression: a case report]. |
PIM1 |
| 5 |
34997652 |
10.1111/ejh.13736 |
2022 |
Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma. |
PIM1 |
| 6 |
35030632 |
10.1182/bloodadvances.2021006410 |
2022 |
Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. |
PIM1 |
| 7 |
35106936 |
10.1002/cam4.4550 |
2022 |
SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. |
PIM1 |
| 8 |
35223507 |
10.3389/fonc.2022.824632 |
2022 |
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. |
PIM1 |
| 9 |
35300216 |
10.2147/JIR.S341355 |
2022 |
The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. |
PIM1 |
| 10 |
35401516 |
10.3389/fimmu.2022.842439 |
2022 |
Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. |
PIM1 |
| 11 |
35415904 |
10.1002/ctm2.808 |
2022 |
PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma. |
PIM1 |
| 12 |
35646048 |
10.3389/fgene.2022.878618 |
2022 |
Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
PIM1 |
| 13 |
35928872 |
10.3389/fonc.2022.932674 |
2022 |
Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma. |
PIM1 |
| 14 |
35937947 |
10.1155/2022/6441139 |
2022 |
Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis. |
PIM1 |
| 15 |
36053490 |
10.1002/hon.3073 |
2022 |
Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma. |
PIM1 |
| 16 |
36081566 |
10.3389/fonc.2022.941347 |
2022 |
Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. |
PIM1 |
| 17 |
32139889 |
10.1038/s41375-020-0766-4 |
2021 |
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. |
PIM1 |
| 18 |
32973328 |
10.1038/s41379-020-00685-7 |
2021 |
The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. |
PIM1 |
| 19 |
33202420 |
10.1182/blood.2020008520 |
2021 |
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. |
PIM1 |
| 20 |
33307035 |
10.1016/j.ajpath.2020.12.001 |
2021 |
PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity. |
PIM1 |
| 21 |
33479306 |
10.1038/s41598-020-80376-0 |
2021 |
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. |
PIM1 |
| 22 |
33581493 |
10.1016/j.ctarc.2021.100310 |
2021 |
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. |
PIM1 |
| 23 |
33747936 |
10.3389/fonc.2021.622648 |
2021 |
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. |
PIM1 |
| 24 |
33777778 |
10.3389/fonc.2021.628807 |
2021 |
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. |
PIM1 |
| 25 |
33945543 |
10.1371/journal.pone.0248886 |
2021 |
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes. |
PIM1 |
| 26 |
34267815 |
10.3892/ol.2021.12883 |
2021 |
<i>In vitro</i> assessment of the efficiency of the PIM-1 kinase pharmacological inhibitor as a potential treatment for Burkitt's lymphoma. |
PIM1 |
| 27 |
34374220 |
10.1002/cjp2.223 |
2021 |
c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma. |
PIM1 |
| 28 |
34625423 |
10.1158/0008-5472.CAN-21-1023 |
2021 |
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. |
PIM1 |
| 29 |
34925435 |
10.3389/fgene.2021.677650 |
2021 |
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. |
PIM1 |
| 30 |
34944954 |
10.3390/cancers13246334 |
2021 |
Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System. |
PIM1 |
| 31 |
35116576 |
10.21037/tcr-20-2525 |
2021 |
Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database. |
PIM1 |
| 32 |
31886867 |
10.1093/jnen/nlz125 |
2020 |
Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. |
PIM1 |
| 33 |
31958486 |
10.1016/j.canlet.2020.01.012 |
2020 |
Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma. |
PIM1 |
| 34 |
32146726 |
10.1002/1878-0261.12662 |
2020 |
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. |
PIM1 |
| 35 |
32201861 |
10.1093/noajnl/vdaa018 |
2020 |
Primary CNS lymphoma commonly expresses immune response biomarkers. |
PIM1 |
| 36 |
32239385 |
10.1007/s11523-020-00710-4 |
2020 |
Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. |
PIM1 |
| 37 |
32315407 |
10.1182/blood.2019003880 |
2020 |
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. |
PIM1 |
| 38 |
32379874 |
10.1182/blood.2020005142 |
2020 |
A targetable cue in T-cell malignancy. |
PIM1 |
| 39 |
32399964 |
10.1002/ijc.33049 |
2020 |
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. |
PIM1 |
| 40 |
32469082 |
10.1002/cncr.32866 |
2020 |
Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. |
PIM1 |
| 41 |
32565964 |
10.3892/ol.2020.11552 |
2020 |
Comprehensive characterization of driver genes in diffuse large B cell lymphoma. |
PIM1 |
| 42 |
32753387 |
10.1158/1535-7163.MCT-20-0160 |
2020 |
PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. |
PIM1 |
| 43 |
32864130 |
10.1186/s40364-020-00214-3 |
2020 |
A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression. |
PIM1 |
| 44 |
33252851 |
10.1002/ctm2.221 |
2020 |
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. |
PIM1 |
| 45 |
30076176 |
10.3324/haematol.2018.199257 |
2019 |
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. |
PIM1 |
| 46 |
30658101 |
10.1016/j.lfs.2019.01.022 |
2019 |
PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway. |
PIM1 |
| 47 |
30829648 |
10.1172/JCI120654 |
2019 |
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. |
PIM1 |
| 48 |
31403034 |
10.3389/fonc.2019.00683 |
2019 |
Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes. |
PIM1 |
| 49 |
31483572 |
10.1111/jcmm.14601 |
2019 |
Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis. |
PIM1 |
| 50 |
31780656 |
10.1038/s41467-019-13315-x |
2019 |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. |
PIM1 |
| 51 |
31806993 |
10.2147/OTT.S227122 |
2019 |
Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review. |
PIM1 |
| 52 |
32245312 |
10.18502/ijaai.v18i6.2181 |
2019 |
Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines. |
PIM1 |
| 53 |
29444501 |
10.1159/000486361 |
2018 |
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. |
PIM1 |
| 54 |
29479063 |
10.1038/s41375-018-0031-2 |
2018 |
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. |
PIM1 |
| 55 |
29496663 |
10.1158/2159-8290.CD-17-0583 |
2018 |
HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. |
PIM1 |
| 56 |
29891112 |
10.1016/j.critrevonc.2018.05.010 |
2018 |
Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. |
PIM1 |
| 57 |
29937999 |
10.18632/oncotarget.25463 |
2018 |
Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. |
PIM1 |
| 58 |
30020405 |
10.1093/abbs/gmy076 |
2018 |
PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression. |
PIM1 |
| 59 |
30185437 |
10.1182/bloodadvances.2018021063 |
2018 |
STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. |
PIM1 |
| 60 |
30209976 |
10.1080/15384101.2018.1522912 |
2018 |
PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. |
PIM1 |
| 61 |
30227305 |
10.1016/j.neo.2018.08.012 |
2018 |
Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes. |
PIM1 |
| 62 |
30370255 |
10.15430/JCP.2018.23.3.109 |
2018 |
PIM Kinase as an Executional Target in Cancer. |
PIM1 |
| 63 |
30463380 |
10.3390/cancers10110459 |
2018 |
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma. |
PIM1 |
| 64 |
27641442 |
10.1016/j.bbadis.2016.09.012 |
2017 |
CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation. |
PIM1 |
| 65 |
28134252 |
10.1038/ncomms14290 |
2017 |
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. |
PIM1 |
| 66 |
28368397 |
10.1038/onc.2017.90 |
2017 |
Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. |
PIM1 |
| 67 |
28415816 |
10.18632/oncotarget.16320 |
2017 |
Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. |
PIM1 |
| 68 |
28479318 |
10.1016/j.jid.2017.04.010 |
2017 |
Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. |
PIM1 |
| 69 |
28698206 |
10.1182/blood-2017-01-760702 |
2017 |
Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. |
PIM1 |
| 70 |
28729093 |
10.1016/j.yexcr.2017.07.019 |
2017 |
PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells. |
PIM1 |
| 71 |
28841204 |
10.1038/bcj.2017.72 |
2017 |
From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. |
PIM1 |
| 72 |
29245897 |
10.18632/oncotarget.18502 |
2017 |
Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum. |
PIM1 |
| 73 |
29262531 |
10.18632/oncotarget.21986 |
2017 |
Mutational profile of primary breast diffuse large B-cell lymphoma. |
PIM1 |
| 74 |
26757737 |
10.1007/s00401-016-1536-2 |
2016 |
Genomic characterization of primary central nervous system lymphoma. |
PIM1 |
| 75 |
26773040 |
10.1182/blood-2015-09-672352 |
2016 |
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. |
PIM1 |
| 76 |
26813676 |
10.1182/blood-2015-11-685032 |
2016 |
Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. |
PIM1 |
| 77 |
27030389 |
10.1182/blood-2015-12-686550 |
2016 |
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. |
PIM1 |
| 78 |
27088431 |
10.1111/cas.12945 |
2016 |
Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia. |
PIM1 |
| 79 |
27198204 |
10.1038/leu.2016.135 |
2016 |
Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. |
PIM1 |
| 80 |
27556513 |
10.18632/oncotarget.11457 |
2016 |
Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. |
PIM1 |
| 81 |
27904766 |
|
2016 |
The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. |
PIM1 |
| 82 |
25189415 |
10.1038/leu.2014.264 |
2015 |
The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. |
PIM1 |
| 83 |
25553374 |
10.2741/E728 |
2015 |
Understanding the functional discrepancy of Pim-1 in cancer. |
PIM1 |
| 84 |
26340096 |
10.1371/journal.pone.0137210 |
2015 |
Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. |
PIM1 |
| 85 |
26643319 |
10.1186/s12943-015-0477-z |
2015 |
Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. |
PIM1 |
| 86 |
23910958 |
10.1016/j.bcmd.2013.07.003 |
2014 |
GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas. |
PIM1 |
| 87 |
24131033 |
10.1517/13543776.2014.848196 |
2014 |
Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update. |
PIM1 |
| 88 |
24240734 |
10.1007/s00401-013-1202-x |
2014 |
Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. |
PIM1 |
| 89 |
24474669 |
10.1158/1078-0432.CCR-13-2062 |
2014 |
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. |
PIM1 |
| 90 |
24547709 |
10.3109/10428194.2014.893303 |
2014 |
Expression of PIM1 protein in chronic lymphocytic leukemia/small lymphocytic lymphoma. |
PIM1 |
| 91 |
24605938 |
10.3109/10428194.2014.900762 |
2014 |
A new model of LMP1-MYC interaction in B cell lymphoma. |
PIM1 |
| 92 |
24756111 |
10.1038/jid.2014.199 |
2014 |
Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome. |
PIM1 |
| 93 |
24970810 |
10.18632/oncotarget.2080 |
2014 |
Mutational analysis of primary central nervous system lymphoma. |
PIM1 |
| 94 |
23360755 |
10.1186/1756-8722-6-12 |
2013 |
Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. |
PIM1 |
| 95 |
23872419 |
10.1016/j.bbamcr.2013.07.010 |
2013 |
Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. |
PIM1 |
| 96 |
24900629 |
10.1021/ml400307j |
2013 |
Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors. |
PIM1 |
| 97 |
21743487 |
10.1038/onc.2011.278 |
2012 |
The proto-oncogene Pim-1 is a target of miR-33a. |
PIM1 |
| 98 |
22101984 |
10.1002/eji.201141987 |
2012 |
Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes. |
PIM1 |
| 99 |
22282239 |
10.1007/s11596-012-0003-0 |
2012 |
PI3K-like kinases restrain Pim gene expression in endothelial cells. |
PIM1 |
| 100 |
22385356 |
10.1111/j.1399-6576.2012.02657.x |
2012 |
Desflurane-induced and ischaemic postconditioning against myocardial infarction are mediated by Pim-1 kinase. |
PIM1 |
Datasets
Models
